Compare Crowdstrike Holdings Inc (CRWD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Crowdstrike Holdings Inc trades at $221.65 (market cap $225.95B), while Regeneron Pharmaceuticals Inc trades at $796.54 (market cap $82.06B). The key difference: Crowdstrike Holdings Inc is far larger — about 2.8× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| CRWD | REGN | |
|---|---|---|
Market Cap | $225.95B | $82.06B |
Sector | Technology | Health |
52-Week High | $225.16 | $812.27 |
52-Week Low | $87.56 | $555.51 |
Enterprise Value | $222.22B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $225.16, up 5.01% in the last session and near its all-time high. The stock exhibits strong technical momentum with bullish moving averages and is trading above key support at $222. Fundamentally, revenue growth remains robust, reaching $3.95 billion in 2025, though profitability is inconsistent with a net margin of -0.6%. Recent positive news includes being named a leader in IDC's MDR market assessment (Business Wire, August 11, 2026) and strong performance at industry events.
The outlook is positive given strong revenue growth and market leadership in cybersecurity, but the stock carries significant risk due to its extreme valuation multiples (P/E of 765) and intense competition. Investment appeal hinges on sustained high growth justifying the premium, while key risks include execution missteps and a broader market pullback.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
